Heart failure drug resistance: scientists test new combinations
NCT ID NCT05753059
First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 2 times
Summary
This study looks at why some people with heart failure don't get rid of excess fluid with standard water pills (diuretics). Researchers will test adding two other types of diuretics—bendroflumethiazide and amiloride—to see if they improve the body's response. Fifty adults with heart failure will receive different drug combinations over several weeks to measure how well their kidneys remove salt and water.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bendroflumethiazide, amiloride, and bumetanide (diuretic drugs)
- What this could lead to
- If successful, this could help doctors choose better diuretic combinations for heart failure patients who don't respond to standard treatment.
- What could go wrong
- This is a small, early-phase study (50 people) focused on understanding mechanisms, not proving long-term benefits. Results may not apply to all heart failure patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Clinical diagnosis of HF 2. No plan for titration/change of heart failure medical or device therapies during the study period. 3. Absence of non-elective hospitalizations in the previous 2 weeks 4. At optimal volume status by symptoms, exam, and dry weight. 5. Serum potassium ≤ 5.0 mmol/L 6. Serum sodium ≥ 130 mEq/L 7. Age \> 18 years 8. Hemoglobin ≥8 g/dL 9. Objective evidence of diuretic resistance to a 10mg bumetanide challenge, defined as: 1. FENa \<10% and total sodium output \<150mmol and 2. At least one of the following criteria: 1\. Chronic home furosemide dose \> or equal to 80mg furosemide equivalents daily 2. eGFR \< 60ml/min 3. Serum chloride \<100mmol/L 4. FENa \<5% and total sodium output \<75mmol on the 2 hour screening Exclusion Criteria: 1. GFR \<20 ml/min/1.73m2 using the CKD-EPI equation or use of renal replacement therapies 2. Use of any non-loop type diuretic in the last 7 days or 5 half lives, with the exclusion of low dose aldosterone antagonist (e.g., spironolactone or eplerenone ≤50 mg). Examples of non-loop diuretics include but may not be limited to acetazolamide (oral or IV, not ophthalmic), metolazone, HCTZ, chlorthalidone, chlorothiazide, indapamide, triamterene, amiloride, finerenone, spironolactone dose \> 50mg day, eplerenone \> 50mg/day, 3. History of flash pulmonary edema requiring hospitalization and treatment with biphasic positive airway pressure or mechanical ventilation or a "brittle" volume sensitive HF phenotype such as an infiltrative or restrictive cardiomyopathy (i.e. amyloid cardiomyopathy, etc). 4. Hemoglobin \< 8 g/dL or symptomatic anemia 5. Pregnant or breastfeeding 6. Inability to give written informed consent or comply with study protocol or follow-up visits 7. Chronic urinary retention limiting ability to perform timed urine collection procedures 8. On Lithium therapy 9. On pimozide or thioridazine 10. Diagnosis of liver failure 11. Contraindications or allergy to sulfonamides 12. Any contraindication to thiazide diuretic or allergy to thiazide or bendroflumethiazide
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heart failure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?